GLG News by Critical Care Physicians
Articles with lock require a subscription to GLG News |
Request a free trial
November 18, 2008Oral Treprostinil: An effective medicine hiding in a study with a challenging design?
Analysis of: Freedom-C Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Fails to Meet Primary Endpoint | ir.unither.com
Author: Robert Aris, Associate Professor of Medicine, University of North Carolina Chapel Hill - CC
This phase III study was done without the benefit of conventional drug development with Phase I and Phase II studies (which would have provided more information about the effective dose) preceding it because pharmacokinetic date from IV and SC dosing studies were used to extrapolate for the...
August 4, 2008
Cure is a strong word
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: GLG Expert Contributor
Cure is a strong wordAnalysis of: Amgen Told to Reword Drug Label | www.nytimes.com
Author: GLG Expert Contributor
It is important to remember that there are many more "treatable" cancers diagnosed than curable cancers. The initiation of chemotherapy after surgical removal of a neoplasm is a signal that there may be undetectable metastatic disease. You are therefore hoping for a cure but accepting the reality....
July 18, 2008Mild PAH improved by early treatment with bosentan
Analysis of: Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. | www.sciencedirect.com
Author: Robert Aris, Associate Professor of Medicine, University of North Carolina Chapel Hill - CC
While functional class II (FC II) PAH patients have been included in previous clinical trials, the EARLY trial is the first study to concentrate (ie recruit exclusively) FC II PAH patients. This is important because the definition of functional class II is that a patient has a sight...
July 2, 2008The Pleitropic Effects of Volatile Anesthetics: Pain and Inhaled Agents?
Analysis of: Why anaesthetics can make the pain worse | www.newscientist.com
Author: Jason Campagna, Director of Clinical Quality and Analytics, Cottage Health System
There are well over 70 Million general anesthetics performed in the US each year, and the majority of these utilize one of four generally used inhaled anesthetic agents (Sevoflurane, Desflurane, Isoflurane and Halothane). How these drugs act to produce "unconsciousness" is largely unknown, but as the...
June 10, 2008Peer reviewed literature on Ambrisentan, a selective ETRA for PAH
Analysis of: Ambrisentan for the Treatment of Pulmonary Arterial Hypertension | circ.ahajournals.org
Author: Robert Aris, Associate Professor of Medicine, University of North Carolina Chapel Hill - CC
This Circulation paper is the first peer reviewed data on the 2 pivotal Phase III trials on ambrisentan that lead the FDA to approving it for the treatment of PAH in July 2007. This paper is critically important since all new research needs to withstand the rigor of peer-review for...
May 19, 2008
Improving anesthetic/surgical outcomes- the role of pharmacoprophylaxis
Analysis of: Higher Risk of Death and Stroke in Patients Given Beta Blockers After Non-Cardiac Surgery (POISE Trial) | pharmalive.com
Author: GLG Expert Contributor
Improving anesthetic/surgical outcomes- the role of pharmacoprophylaxisAnalysis of: Higher Risk of Death and Stroke in Patients Given Beta Blockers After Non-Cardiac Surgery (POISE Trial) | pharmalive.com
Author: GLG Expert Contributor
To most in anesthesia, a "good anesthetic" is when the patient is delivered to the post anesthesia care unit in a stable fashion. However, it may be more complicated and success is determined by 30-180 day markers of myocardial or CNS morbidity. Unfortunately, this type of followup is not...
April 2, 2008
Singulair suicide story won't kill Merck
Analysis of: FDA Investigating Possible Link Between Singulair and Suicide | www.foxnews.com
Author: Michael Wechsler, Associate Physician in Pulmonary and Critical Care, BRIGHAM AND WOMEN'S HOSPITAL
Singulair suicide story won't kill Merck
Analysis of: FDA Investigating Possible Link Between Singulair and Suicide | www.foxnews.com
Author: Michael Wechsler, Associate Physician in Pulmonary and Critical Care, BRIGHAM AND WOMEN'S HOSPITAL
Singulair helps millions of people suffering from asthma. While there are a few sporadic cases of suicide and depression among the millions of patients taking singulair, no causal link has been established and there is no clear mechanism of how singulair might even cause such effects. In fact,...
March 28, 2008Aspect Medical Systems in the Spotlight- The Bis Monitor, Medical Need and The Capital Markets
Analysis of: Anesthesia Awareness and the Bispectral Index | content.nejm.org
Author: Jason Campagna, Director of Clinical Quality and Analytics, Cottage Health System
1. The market for "depth of anesthesia" monitors has depended very much on marketing and public perception of the problem. This article shines a bright light on the more objective issues of utility and efficacy. 2. Aspect Medical has made a number of mis-steps over the years that have alienated them...
December 6, 2007
The impact in disease prevention efforts is how you identify root problems
Analysis of: CBO: Medicare and Medicaid spending growth unsustainable | www.ama-assn.org
Author: GLG Expert Contributor
The impact in disease prevention efforts is how you identify root problemsAnalysis of: CBO: Medicare and Medicaid spending growth unsustainable | www.ama-assn.org
Author: GLG Expert Contributor
Medicare and Medicaid today are predominantly reactive disease diagnosis and management programs, usually in late stages. That form of care leads to the significant growth of healthcare expenditure (currently estimated at 8% GDP). The future of cost control is disease prevention. Many diseases are only...
October 29, 2007
The impact of HSD1 inhibitor on decreasing diabetes, hypertension, obesity, heart disease and their complications
Analysis of: Vitae Pharmaceuticals and Boehringer Ingelheim announce a major collaboration to develop and commercialize novel treatments for diabetes and metabolic diseases | www.pipelinereview.com
Author: GLG Expert Contributor
The impact of HSD1 inhibitor on decreasing diabetes, hypertension, obesity, heart disease and their complicationsAnalysis of: Vitae Pharmaceuticals and Boehringer Ingelheim announce a major collaboration to develop and commercialize novel treatments for diabetes and metabolic diseases | www.pipelinereview.com
Author: GLG Expert Contributor
The development of HSD1 inhibitors respresents a promising advance in managing diabetes and the metabolic syndrome comprising of obesity, hypertension, and difficult regulation of serum glucose levels. Control of the problems of diabetes and the metabolic syndrome would compose the major components...
Page : 1 2 3 Next1 to 10 of 29
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Personal medicine is goal of Eli Lilly & Co.
www.azcentral.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008